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Plan Quality and Treatment efficiency
for radiosurgery to Multiple Brain
Metastases: non-coplanar rapidarc
vs. gamma Knife
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Objectives: This study compares the dosimetry and efficiency of two modern radiosurgery [stereotactic radiosurgery (SRS)] modalities for multiple brain metastases [Gamma
Knife (GK) and LINAC-based RapidArc/volumetric modulated arc therapy], with a special
focus on the comparison of low-dose spread.
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Methods: Six patients with three or four small brain metastases were used in this study.
The size of targets varied from 0.1 to 10.5 cc. SRS doses were prescribed according
to the size of lesions. SRS plans were made using both Gamma Knife® Perfexion and
a single-isocenter, multiple non-coplanar RapidArc®. Dosimetric parameters analyzed
included RTOG conformity index (CI), gradient index (GI), 12 Gy isodose volume (V12Gy)
for each target, and the dose “spread” (Dspread) for each plan. Dspread reflects SRS
plan’s capability of confining radiation to within the local vicinity of the lesion and to not
spread out to the surrounding normal brain tissues. Each plan has a dose (Dspread),
such that once dose decreases below Dspread (on total tissue dose–volume histogram),
isodose volume starts increasing dramatically. Dspread is defined as that dose when
volume increase first exceeds 20 cc/0.1 Gy dose decrease.
results: RapidArc SRS has smaller CI (1.19 ± 0.14 vs. 1.50 ± 0.16, p < 0.001)
and larger GI (4.77 ± 1.49 vs. 3.65 ± 0.98, p < 0.01). V12Gy results were comparable
(2.73 ± 1.38 vs. 3.06 ± 2.20 cc, p = 0.58). Moderate to lower dose spread, V6, V4.5,
and V3, were also equivalent. GK plans achieved better very low-dose spread (≤3 Gy)
and also had slightly smaller Dspread, 1.9 vs. 2.5 Gy. Total treatment time for GK is
estimated between 60 and 100 min. GK treatments are between 3 and 5 times longer
compared to RapidArc treatment techniques.
conclusion: Dosimetric parameters reflecting prescription dose conformality (CI), dose
fall off (GI), radiation necrosis indicator (V12Gy), and dose spread (Dspread) were compared
between GK SRS and RapidArc SRS for multi-mets. RapidArc plans have smaller CI but
larger GI. V12Gy are comparable. GK appears better at reducing only very low-dose spread
(<3 Gy). The treatment time of RapidArc SRS is significantly reduced compared to GK SRS.
Keywords: VMAT, RapidArc, Gamma Knife, SRS, brain metastasis
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INTRODUCTION

Imaging Protocol

Our treatment planning employed both high-quality magnetic
resonance imaging (MRI), from a 1.5-T or 3.0-T scanner, and
high-resolution computed tomography (CT) images. The CT
technique utilized a 512 × 512-pixel resolution and slice thickness of 1.25 mm to reduce partial volume effects. Contrast
enhanced, thin cut (1.0–1.5 mm thickness) 3D T1-weighted MRI
was acquired to optimize planning fidelity. Target and normal
structure contours were outlined based on the high-resolution
MRI and approved by an attending neurosurgeon and radiation
oncologist. The contoured MR images were then fused to the CT.
The same sets of images and structures were used in both Elekta
GammaPlan and Varian Eclipse TPSs.

Brain metastases represent the most frequent brain tumor and are
a significant cause of morbidity and mortality. Surgery, wholebrain radiation treatment (WBRT), and stereotactic radiosurgery
(SRS) are all used in the treatment of brain metastases (1–9).
Radiosurgery has emerged as a common treatment modality for
brain metastases since the introduction of Gamma Knife (GK)
(10), but now advances in technology permits newer techniques,
such as Cyberknife® and linear accelerator (LINAC)-based volumetric modulated arc therapy (VMAT) treatment.
Linear accelerator-based systems are capable of achieving
delivering treatment techniques common to GK SRS. These
include (a) an ensemble of convergent beams or arcs used to target a circumscribed, well-defined lesion, (b) high doses delivered
to the planning target volume (PTV), and (c) steep dose gradients
created at the margin of the tumor and normal tissue, thus ensuring a low dose outside the target. The common techniques of
LINAC SRS include the use of multiple conformal arcs or multiple
static intensity modulated beams (IMRT), which further evolved
into VMAT (11), to treat a single target positioned at the LINAC
isocenter. The treatment time for one target typically ranges from
15 to 20 min, which becomes the limit factor to treat more than
4–5 brain metastases in a single session.
Some studies proposed treating multiple brain metastases SRS
with a single virtual isocenter using VMAT technique (12–19), and
some compared to GK (16–19). While some previous studies have
appeared to show GK as superior to LINAC SRS with regard to normal
brain exposure (16–18), a more recent study suggested equivalent
low-dose spread and increased delivery efficiency (19) when using
non-coplanar RapidArc [one of the VMAT techniques implemented
by Varian Eclpise treatment planning system (TPS)]. However, the
low-dose spread in this study was defined as 25% of prescription dose
(4.5 Gy as the lowest comparison dose), which may not be as low as
the dose used by other controversy studies. Therefore, we performed
the current study to evaluate the dosimetry and efficiency of these
two modalities – GK and LINAC single-isocenter non-coplanar
RapidArc SRS for multiple brain metastases, with a special focus on
the comparison of very low-dose spread (≤3 Gy). The other difference in our study is that a newer model of GK (Perfexion™) is used
as compared to the older model (C/4C) used in literature (19).

Radiation Dose

Stereotactic radiosurgery doses, prescribed according to size of
the lesions, varied from 15 to 24 Gy according to RTOG 9508
(20). Radiation doses were modified if unable to meet nearby
organ at risk (OAR) tolerance, including optic nerve and chiasm
max dose of 10 Gy and brainstem max dose of 12 Gy. Prescription
dose and tumor volume of each target are listed in Table 1.

Gamma Knife Treatment Planning

Gamma Knife plans were performed for all patients using the
Elekta GammaPlan TPS (version 10.1) for a Gamma Knife
Perfexion treatment unit. The Perfexion has 192 Co-60 sources,
which are placed on eight sectors. Each position corresponds to
a different size collimator. Each sector has 24 sources and three
different sizes of open collimators are available for each source
(16, 8, and 4 mm) as well as a blocked collimator. Because each of
the eight sectors can move independently, it is possible to create
plans with composite multiple shots where each sector is of different collimator size. Treatment plan of each lesion starts from
automatic shots fill in with composite small to medium sized
TABLE 1 | Prescription dose and tumor volumes of each target in this
study.
Patient
no.

MATERIALS AND METHODS

No. of
targets

Total tumor vol.
(cc)

Tumor vol.
(cc)

Prescription
dose (Gy)

1

3

5.32

2

3

2.08

3

3

1.19

4

3

5.13

5

3

11.14

6

4

1.70

2.53
0.81
1.98
0.41
0.51
1.16
0.41
0.52
0.26
4.62
0.12
0.39
10.51
0.35
0.28
0.68
0.56
0.46
0.4

16
24
20
24
24
18
24
24
24
18
24
24
15
24
24
24
24
24
24

Patients

We used the image data of six patients with three to four brain
metastases who received SRS treatment at our institution. The
study was approved by our Institutional Review Board (IRB).
The cases were planned with GammaPlan®, the Gamma Knife
Perfexion TPS (Elekta AB, Stockholm Sweden), and Eclipse™
TPS using RapidArc®, a particular implementation of VMAT
(Varian Medical Systems, Palo Alto, CA, USA) on Varian delivery
systems, the more recent versions of which, allow for the delivery
of multiple non-coplanar arcs. Each of the GK plans was designed
by an experienced GK physicist and approved by an attending
neurosurgeon and radiation oncologist. All RapidArc plans were
generated by an experienced physicist dedicated to SRS.

Frontiers in Oncology | www.frontiersin.org
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collimators depending on the volumes of the target, followed by
an optimization with inverse planning setting of 99% coverage.
After the initial optimization, it usually achieves ~95% coverage
with dose distribution that is not very conformal. Planner adjustments are then introduced to achieve >99.5% volume coverage
by the prescription dose and a more conformal dose distribution.
Adjustment includes changing position and weight of each existing shot and adding new shots. Multiple shots plans were usually
used to increase conformity, rather than fewer shots to minimize
treatment time. All targets are prescribed to 50% isodose line. The
“TMR 10” dose algorithm is used in Gamma plan calculation.
Detailed GK planning parameters are listed in Table 2.

7.0-cm peripheral regions (23, 24). One isocenter was used for all
targets and was placed at the center of mass of all targets determined by the TPS. Each lesion must have >99.5% volume covered
by prescription dose. “AAA” algorithm with heterogeneous correction, 1 mm calculation grid is used for final dose calculation.

Evaluation Tools

Dosimetric parameters for analysis included RTOG conformity
index (CI), gradient index (GI), 12 Gy isodose volume (V12Gy)
for each target, and dose spread (Dspread) for each plan. RTOG
CI = PV/TV, where PV is the prescription volume and TV is the
target volume (25). Paddick GI = PV50%/PV, where PV50% is
50% of the prescription isodose volume and PV is the prescription
volume (26). Dspread reflects the SRS plan’s capability of confining
radiation to within the lesions’ local vicinity minimizing spread to
surrounding normal brain tissues. Each plan has a dose (Dspread)
on the total tissue DVH, such that once dose drops below Dspread,
the isodose volume starts increasing dramatically. In this study,
Dspread is defined at the dose at which the volume increase first
exceeds 20 cc/0.1 Gy drop in dose. For the Eclipse TPS, it is the dose
at 2 cc/cGy on a differential DVH curve for normal brain tissue.
Treatment times for RapidArc SRS were estimated using the summation of patient setup time, image guidance and verification (IGRT)
time, and radiation delivery time. Radiation delivery is based on the
total dose divided by 1400 cGy/min dose rate. Treatment time for
GK SRS was estimated using the summation of patient setup time,
shot transition time, and net beam-on time. Beam-on time assumes
new Co-60 sources whose dose rate is 360 cGy/min.
In order to compare the results across different TPSs, the
three-dimensional (3D) radiation dose matrix of both GK and
RapidArc SRS plans were exported in DICOM RT format to a
third party system (MIMVISTA). Both dose matrices encompass
the entire brain at a dose calculation resolution of 1.0 mm.

RapidArc Treatment Planning

For all patients in the study, RapidArc plans were optimized using
four to six non-coplanar partial arcs (21). Collimator and couch
angles as well as single arc lengths were optimized for each individual case with small adjustments to our established template.
The detailed planning parameters for each case are listed in
Table 3. Inverse planning was performed with the Varian Eclipse
TPS (version 11) and dose calculation with a grid resolution of
1.0 mm. Three layers of tuning rinds, as described by Clark et al.
(14), were constructed to control the dose–volume constraints
corresponding to the high-, mid-, and low-dose levels, where
“high” is the prescription dose of each target, “medium” the 12-Gy
dose level, and “low” the 6-Gy dose level. The outer diameters
of each layer of rinds depend on the size of the target. All plans
were constructed using the 6-MV flatten filter free (FFF) beam,
generated by a TrueBeam STx radiosurgery system equipped with
a high-definition (2.5 mm) multileaf collimator (MLC). The High
Intensity Mode unflattened 6 MV beam delivers radiation at a dose
rate of 1400 cGy/min. Prendergast first showed the efficiency benefit of unflattened beams for cranial treatments (22). The HD120
MLC™ has 120 leaves with a leaf width projected at isocenter
of 2.5 mm for the central 8.0-cm region and 5.0 mm for the two

Statistics

Prism® version 5.0 was used to process data and perform statistical
analyses. Direct comparison was performed via paired Wilcoxon
signed rank test; multivariate regression was performed via least
squares regression with an identity link function. p-values <0.05
were considered significant.

TABLE 2 | Planning parameters for Gamma Knife Perfexion plans.
Patient
no.
1
2
3
4
5
6

No. of
targets

Number of
shots

Beam-on
time (min)

Est. total tx time
(min)

3
3
3
3
3
4

43
15
4
19
26
10

83.5
72.2
47
70
93
64

100
87
56
84
112
77

RESULTS
Clinical acceptable plans were achieved by both GK SRS and
RapidArc SRS. Figure 1 shows the isodose distribution of both
GK plan and RapidArc plan for patient #1, a typical patient.

TABLE 3 | Planning parameters for single-isocenter VMAT plan.
Patient
no.
1
2
3
4
5
6

No. of
targets

No. of
arcs

Table angles (Varian
IEC Scale)

Arc length

Monitor
units (MU)

Beam-on
time (min)

Est. total tx
time (min)

3
3
3
3
3
4

4
6
6
5
5
5

45, 0, 335, 300
70, 40, 10, 0, 335, 305
50, 25, 0, 340, 315, 290
80, 45, 20, 353, 300
60, 20, 345, 310, 270
70, 40, 10, 0, 300

170, 120, 140, 140
160, 150, 40, 130, 160, 150
160, 160, 130, 140, 140, 150
140, 140, 150, 140, 150
120, 120, 120, 140, 140
170, 170, 170, 140, 140

7000
8300
9600
10,130
8660
9750

5.0
5.9
6.9
7.2
6.2
7.0

15
18
21
22
19
21
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FIGURE 1 | Isodose distribution of a single-isocenter VMAT (RapidArc) SRS plan (A) and Gamma Knife (B) Perfexion plan for the same patient
(patient #1). Isodose lines are 24, 20, 16, 12, 6, and 3 Gy. (A) Isodose distribution of a single-isocenter VMAT (RapidArc) SRS plan for patient #1. (B) Isodose
distribution of Gamma Knife Perfexion SRS plan for patient #1.

Figure 2 shows the dose–volume histogram of three lesions and
normal brain tissues of both plans for this patient.
RapidArc SRS has smaller CI (1.19 ± 0.14 vs. 1.50 ± 0.16,
p < 0.001), however, a larger GI (4.77 ± 1.49 vs. 3.65 ± 0.98,
p < 0.01). The larger GI values for the RapidArc SRS plan are not
because they have larger 50% prescription isodose volume but
because they all have smaller 100% prescription isodose volume.
Therefore, instead of comparing GI values, which are not a valid
comparison, the absolute volume that receives more than 12 Gy

Frontiers in Oncology | www.frontiersin.org

(V12Gy) is compared in our study. V12Gy was chosen because it is a
known predictor of radiation toxicity in normal brain tissues (27).
The V12Gy of each individual targets were comparable between
GK and RapidArc, 3.06 ± 2.20 vs. 2.73 ± 1.38 cc, respectively,
p = 0.58. Table 4 shows the CI, GI, and V12Gy of each individual
targets. To further evaluate the impact on the dose to normal
brain tissue outside the target, we compared multiple dosimetric
parameters for low-dose spread. Lower dose spread V6, V4.5, and
V3 were also equivalent (Table 5).

4
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FIGURE 2 | Dose–volume histogram (DVH) comparison of a single-isocenter VMAT (RapidArc) SRS plan and Gamma Knife Perfexion plan for the
same patient (patient #1) showing background dose to normal tissue and DVH for the 16, 20, and 24 Gy treatment of the larger to the smaller target,
respectively.

To further evaluate the low-dose spread between the two techniques, we also evaluated the dose to 100, 200, and 300 cc normal
brain tissues (Table 5). The dose to 100 cc (D100cc) is equivalent.
The dose to 200 cc (D200cc) is approaching a statistically significant
difference and favors GK plans, 2.6 vs. 3.2 Gy, p = 0.06. The dose
to 300 cc normal brain tissue (D300cc) is better for GK plans, 2 vs.
2.6 Gy, p < 0.05. However, the very small absolute difference of
0.6 Gy is not considered clinically significant in either case.
In addition, we also used the parameter of Dspread, which is
defined at the dose when volume increase exceeds 20 cc/0.1 Gy
dose decrease, for easy comparison of low-dose spread between
plans. GK plan had smaller Dspread, 1.9 vs. 2.5 Gy, p = 0.01.
Again, the small difference at this very low-dose level is not
expected to be clinically significant.
We also evaluated the treatment delivery time for both GK and
RapidArc SRS plans. For these six cases, beam-on time averages
~72 min for GK SRS and 6.4 min for RapidArc SRS (Table 5).
Total treatment time for GK is estimated between 56 and 112 min
including setup and shot transition time, based on new radiation sources. Total treatment time for RapidArc SRS is estimated
between 15 and 22 min including setup, imaging guidance, and
treatment table rotation time between arcs. It is average ~4.5
times shorter compared to GK treatment (Tables 2 and 3).

radiosurgery. C-arm LINAC treatment machines have the advantage of being versatile, capable of delivering treatment to extracranial sites as well as intracranial sites and capable of delivering
multi-fraction treatment with easily reproducible non-invasive
target immobilization and localization. With the availability of
image-guided radiation therapy, advances in computer science,
and improvement of treatment delivery hardware, such as highdefinition MLCs, which allow for the simultaneous delivery of
shaped dose to multiple targets, modern LINACs are able to
achieve the same degree of accuracy and precision of the GK but
with more treatment efficiency. With the more recent development of VMAT optimization planning capability, LINACs are
able to simultaneously treat multiple targets with high plan quality and even greater efficiency. This becomes particular appealing
with SRS for multiple brain metastases. In our current study, we
have demonstrated, along with others (19), that RapidArc-based
treatment planning can achieve the same target coverage as GK,
with similar clinically acceptable dosimetry results (Table 4).
Even with multiple-shot optimized plans, the CI of GK plans are
still inferior to that of RapidArc plans. The major concern for
the RapidArc plans is the very low-dose spread to the normal
brain tissue outside the treatment fields. Several other studies
have evaluated this and had slightly different conclusions. We
paid special attention to the low-dose spread in the current
study. With our analysis, the statistical difference in low-dose
spread is only at a very low-dose level, particularly <3 Gy. This
small amount of very low-dose spread is not considered clinically significant and is comparable to the dose of one fraction of

DISCUSSION
Since the invention of GK in the 1950s, multiple C-arm LINAC
treatment machines have been commonly used for cranial
Frontiers in Oncology | www.frontiersin.org
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TABLE 4 | Comparison of conformity index and normal tissue V12Gy of each target in this study.
Normal tissue
Patient #

1

2

3

4

5

6

Target #

Target vol. (cc)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Conformity index

2.53
0.81
1.98
0.41
0.51
1.16
0.41
0.52
0.26
4.62
0.12
0.39
10.51
0.35
0.28
0.68
0.56
0.46
0.4

Mean
SD

V12 (patient composite)
V6
V4.5
V3
D100
D200
D300
Dspread
Beam-on time
Est. total tx time

RPA

GKP

PRA

GKP

RPA

1.62
1.63
1.60
1.27
1.43
1.78
1.54
1.35
1.58
1.29
1.83
1.51
1.36
1.49
1.68
1.41
1.46
1.41
1.37
1.50
0.16
p

1.15
1.17
1.14
1.12
1.14
1.38
1.15
1.10
1.23
1.15
1.67
1.26
1.07
1.26
1.21
1.09
1.11
1.17
1.00
1.19
0.14
<0.001

3.42
3.75
3.21
3.46
2.82
2.75
2.56
3.71
3.88
3.64
3.32
2.76
2.69
4.60
6.40
4.38
4.95
4.45
2.67
3.65
0.98
p

4.28
4.63
3.92
5.04
4.55
4.54
4.68
4.25
5.34
3.69
10.30
5.14
2.58
5.20
5.38
4.07
4.55
4.19
4.30
4.77
1.49
0.01

4.80
4.14
5.76
1.39
1.55
2.72
1.20
2.08
1.33
7.23
0.61
1.24
8.64
2.04
2.73
3.52
3.50
2.43
1.28
3.06
2.20
p

3.45
3.59
4.51
1.91
2.13
3.21
1.91
2.19
1.54
6.48
1.94
2.13
5.34
1.94
1.55
2.33
2.26
1.80
1.58
2.73
1.38
0.58

One of the most significant advantages of RapidArc compared
to GK is the efficiency of treatment delivery. In our current study,
we included patients with up to four brain metastases, based
on level-1 evidence (5–7). For RapidArc SRS, beam-on time is
<10 min for all the patients. Including setup and image-guidance
procedures, the total treatment time can easily be <15–20 min.
This efficiency benefit is primarily due to three key features of
modern LINAC technology in this study: (1) single-isocenter–
non-coplanar VMAT (RapidArc SRS) treatment for all the targets
(14, 19) vs. multiple isocenters corresponding to each individual
target; (2) high-resolution MLC (HD120 MLC) – providing
simultaneous high-resolution beam shaping (23, 24) of all the
targets simultaneously from any angle vs. one target at a time; and
(3) high dose rate (22) provided by the High Intensity Mode vs.
the maximum dose rate of Co-60, which declines by 50% of max
over 5 years. This not only increases the machine utilization but
also improves the patient experience, particularly with a frameless immobilization system. The delivery efficiency of GK can be
improved by using a large helmet size and less complex plans with
fewer shots. However, this will result in a lower conformity index
and increases low-dose spread. Recent high-level evidence from
Japan suggests that SRS alone is safe and appropriate to consider
for patients with up to 10 brain metastases (34). The advantage of
delivery efficiency of RapidArc would be even greater.
Compared to other studies using single-isocenter coplanar
VMAT (15, 16, 18) techniques, this study used a single-isocenter,
multiple arc technique, with multiple treatment angles. And
compared to previous published studies using RapidArc SRS
single-isocenter multi arc VMAT techniques (13, 14, 19), the arc

RapidArc

Mean

Std.

Mean

Std.

p

10.85
36.9
86.7
160.8
4
2.6
2
1.9
71.6
85.9

7.2
16.9
29.8
55.7
0.9
0.6
0.4
0.73
15.9
19.1

9.7
36.3
99
224
4.6
3.2
2.6
2.5
6.4
19.3

5.1
14.7
27.3
53
0.6
0.5
0.4
0.2
0.8
2.6

0.63
0.96
0.15
0.1
0.3
0.06
<0.05
0.01
<0.01
<0.01

whole-brain irradiation. Extensive evidence have demonstrated
that this is below the normal tissue tolerances of all sensitive brain
structures, such as cochlea, optic nerve, chiasm, brainstem, and
hippocampus (28–32). A recent assessment of the true risk of
very low doses to normal brain tissues is highlighted in a recent
study from the University of Florida (33). They analyzed 23 years
of LINAC-based SRS data to address the long-term malignancy
risk of low doses to normal brain compared to epidemiological
brain tumor data in Florida. An analysis of the 627 cranial SRS
patients (out of a total cohort of 2369 analyzed), who had five or
more years of follow-up, showed that there was no increased risk
of malignancy compared to the general population.

Frontiers in Oncology | www.frontiersin.org

V12Gy (cc)

GKP

TABLE 5 | Dosimetric parameters of Gamma Knife SRS and RapidArc
SRS radiation treatment plans in this study.
Gamma Knife

Gradient index

6
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geometry utilized in the current study is different. Multiple (4–6)
non-coplanar partial arcs, between 110° and 150° arc lengths,
were used, which avoids a transverse plane full 360° arc. The
rationale is that for the transverse plane full 360° arc, since the
second half arc enters through the exit of the first half arc, the
normal brain tissue will receive more doses. By offsetting the
arcs from the transverse plane, parallel-opposed beams will be
avoided and the normal tissue isodose volume can be reduced, as
Schell et al.’s study showed previously (21).
The target volumes in this study ranged from 0.1 to 10.5 cc,
with most of them <2 cc (small targets). A recent planning comparison study for large target fractionated SRT using VMAT and
GK for brain metastases and gliomas showed that GK produce
better dose distribution for target volumes below 15 cc, while
VMAT results in better dose conformity to the target and lower
doses to the OARs for larger or irregular volumes (35).
It is worthwhile to point out that while the prescription dose
covering the target volume is the same between GammaKnife
and RaridArc SRS plans, the dose heterogeneity within the planning target volume (PTV) is much different. GK plan for each
target in this study is prescribed to the standard 50% isodose
line, which implies that the maximum dose within the PTV
is twice as high as the prescription dose. RapidArc plan is an
inverse planning process; the optimization goal to each PTV
set by the planner is to have at least 99.5% volume receiving
prescription dose. No constraint is set on the maximum dose.
Therefore, there is no manual selection of a specific normalization isodose line for RapidArc plans. The ratio of prescription
dose to maximum dose for the 19 targets in RapidArc plans is
63 ± 5% (range 54–74%).

up to four metastases. RapidArc SRS plans have smaller CI but
larger GI. V12Gy are comparable. GK SRS performs better at reducing very low-dose spread. However, the lowest doses to normal
tissues in properly optimized RapidArc plans are not considered
clinically significant (<3 Gy). While several prior studies demonstrated the clinical feasibility of delivering high quality plans for
single-isocenter RapidArc SRS for multiple cranial metastases,
they did not address the question of very low dose to normal
brain. This study quantified the low-dose spread in the case of
three or four metastases. It also demonstrated that low dose is
not clinically significant, even though it is larger than that of
GK. On the other hand, the treatment time of RapidArc SRS
is significantly reduced compared to GK SRS. Treatment time
for SRS to multiple cranial metastases will become increasingly
more relevant with the trend toward treating greater numbers of
brain metastases in a single SRS session and as systemic therapies
targeting the primary cancer succeed in extending survival in this
increasing population of patients.
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